Golimumab (gol) (DrugBank: Golimumab)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 56 | ベーチェット病 | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04218565 (ClinicalTrials.gov) | February 15, 2020 | 8/12/2019 | Golimumab for the Treatment of Refractory Behcet's Uveitis | Efficacy and Safety of Golimumab in the Treatment of Refractory Uveitis in Patients With Behcet's Disease | Behcet Syndrome;Uveitis | Biological: Golimumab (GOL) | Wenjie Zheng | NULL | Recruiting | 18 Years | 65 Years | All | 9 | Phase 2 | China |